When Everything Falls, These Two Rise | IT and Pharma

On a day when Nifty Metal is the worst-performing sector, Nifty IT and Nifty Pharma are outperforming — rising even as the broader index trades below 24,200. This is now the third consecutive session in which IT and pharma have provided the floor for the market while metals and cyclicals lead the selling.

The pattern has been remarkably consistent through August. Every time crude rises, bond yields climb, or geopolitical uncertainty spikes — which has been often — defensive technology and healthcare names absorb buying while cyclicals and financials face selling. The Nifty IT index has gained over 21 per cent from its July 1 low of 25,699, while the Nifty Metal index — which was the market's darling in June — has given back nearly all of its post-conflict recovery in the last two weeks. For IT specifically, the recovery has a fundamental underpinning. India's July retail inflation came in at 4.45 per cent — above the RBI's 4 per cent target — driven by higher energy prices from the Middle East conflict and rupee pressure. A weaker rupee is precisely the condition under which IT exporters see their rupee-denominated earnings improve without any change in underlying demand, making the sector structurally attractive when currency weakens. For pharma, the defensive case is even simpler. Healthcare spending is inelastic — neither crude oil prices nor US-Iran tensions reduce the demand for Sun Pharma's specialty drugs or Dr. Reddy's biosimilars. In a market searching for certainty, these two sectors are the closest thing to an anchor that the Nifty currently offers.